Yaron Pereg
CEO
Claimed by owner KAHR Medical
Former names:
Fusion Proteins for Treating Cancer and Autoimmune Diseases
KAHR Medical
www.labiotech.eu
•
Nov 18, 2022
MIF invests in KAHR to explore lead immunotherapy drug for multiple myeloma
www.prnewswire.com
•
Feb 17, 2022
KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers
www.prnewswire.com
•
Jun 16, 2021
KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
www.prnewswire.com
•
Jun 2, 2021
Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate
www.prnewswire.com
•
May 26, 2021
KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR's Lead Anti-CD47 Candidate in Blood Cancers
www.prnewswire.com
•
Apr 1, 2021
KAHR Announces Exclusive Licensing Agreement with Thomas Jefferson University for Novel Platform of Bi- and Tri-Specific Fusion Proteins for Cancer Immunotherapy
www.jpost.com
•
Nov 12, 2020
https://www.jpost.com/health-science/jerusalem-based-firm-starts-clinical-trials-for-cancer-treatment-648952
www.prnewswire.com
•
Oct 15, 2020
KAHR Announces Addition of Prof. Hagop M. Kantarjian to Its Clinical Advisory Board
www.timesofisrael.com
•
Aug 16, 2020
KAHR Medical gets FDA nod to start human trials for cancer drug
www.calcalistech.com
•
Feb 25, 2020
Cancer Treatment Company KAHR Medical Raises $18 Million
www.biospace.com
•
Sep 9, 2019
KAHR Medical Announces Clinical Trial Collaboration to Evaluate DSP107 in Combination With a PD-L1 Checkpoint Inhibitor in Advanced Lung Cancer Patients BioSpace
www.israel21c.org
•
May 16, 2016
Canada-Israel sign business deals worth $87 million
www.globes.co.il
•
Dec 15, 2015
Israeli cancer treatment co KAHR Medical raises $12m
About
KAHR is developing immuno-oncology drug candidates for the treatment of multiple types of cancer. Its lead product, DSP107, is a CD47x41BB targeting compound that simultaneously targets cancer cells, weakens their innate defenses, and activates an effective local response of both innate and adaptive immunity.
KAHRs technology platform is based on multifunctional immuno-recruitment proteins (MIRP) that utilize overexpression of checkpoint antigens on cancer cells to selectively target and bind to the tumor. MIRPs bridge cancer cells to immune cells to produce a targeted synergistic effect by combining immune checkpoint inhibition with localized immune cell activation, unmasking cancer cell camouflage to enable innate immune response while recruiting the adaptive immune system to bind and selectively kill the cancer cells.
In August 2020, KAHR Medical received FDA clearance to begin clinical trials on its immunotherapy drug to battle cancer.
KAHRs technology platform is based on multifunctional immuno-recruitment proteins (MIRP) that utilize overexpression of checkpoint antigens on cancer cells to selectively target and bind to the tumor. MIRPs bridge cancer cells to immune cells to produce a targeted synergistic effect by combining immune checkpoint inhibition with localized immune cell activation, unmasking cancer cell camouflage to enable innate immune response while recruiting the adaptive immune system to bind and selectively kill the cancer cells.
In August 2020, KAHR Medical received FDA clearance to begin clinical trials on its immunotherapy drug to battle cancer.
Employees
Product stage
Primary Sector
Life Sciences & HealthTech
Products
DSP106, DSP107, DSP105
Geographic markets
United States, Europe
News
(13)
www.labiotech.eu
•
Nov 18, 2022
MIF invests in KAHR to explore lead immunotherapy drug for multiple myeloma
www.prnewswire.com
•
Feb 17, 2022
KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers
www.prnewswire.com
•
Jun 16, 2021
KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
www.prnewswire.com
•
Jun 2, 2021
Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate
www.prnewswire.com
•
May 26, 2021
KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR's Lead Anti-CD47 Candidate in Blood Cancers
www.prnewswire.com
•
Apr 1, 2021
KAHR Announces Exclusive Licensing Agreement with Thomas Jefferson University for Novel Platform of Bi- and Tri-Specific Fusion Proteins for Cancer Immunotherapy
www.jpost.com
•
Nov 12, 2020
https://www.jpost.com/health-science/jerusalem-based-firm-starts-clinical-trials-for-cancer-treatment-648952
www.prnewswire.com
•
Oct 15, 2020
KAHR Announces Addition of Prof. Hagop M. Kantarjian to Its Clinical Advisory Board
www.timesofisrael.com
•
Aug 16, 2020
KAHR Medical gets FDA nod to start human trials for cancer drug
www.calcalistech.com
•
Feb 25, 2020
Cancer Treatment Company KAHR Medical Raises $18 Million
www.biospace.com
•
Sep 9, 2019
KAHR Medical Announces Clinical Trial Collaboration to Evaluate DSP107 in Combination With a PD-L1 Checkpoint Inhibitor in Advanced Lung Cancer Patients BioSpace
www.israel21c.org
•
May 16, 2016
Canada-Israel sign business deals worth $87 million
www.globes.co.il
•
Dec 15, 2015
Israeli cancer treatment co KAHR Medical raises $12m
The Team
(6)
YP
AF
Adam Foley-Comer
CMO
AC
Ayelet Chajut
CTO
IP
Iris Pecker
VP CMC
RT
Rinat Tabakman
VP Development
OG
Oren Gez
VP Strategy & Corporate Development
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Private Equity Funding
B Round
$12M
Dec 2015
4 Investors
$12M
C Round
$18M
Feb 2020
5 Investors
$18M
Undisclosed Round
$46.5M
Jun 2021
10 Investors
$46.5M
E Round
$12.5M
Jun 2022
2 Investors
$12.5M
Others
Academic Techonology
Sep 2005
undefined
Fusion proteins for treating cancer and autoimmune diseases
Media gallery
(1)
Kahr Medical
Locations
Israel
Hadassah Ein Kerem, Jerusalem, Israel
Locations
Israel
Hadassah Ein Kerem, Jerusalem, Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,